Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Wilms’ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease
Vishwaraj Sontake, Rajesh K. Kasam, Debora Sinner, Thomas R. Korfhagen, Geereddy B. Reddy, Eric S. White, Anil G. Jegga, Satish K. Madala
Vishwaraj Sontake, Rajesh K. Kasam, Debora Sinner, Thomas R. Korfhagen, Geereddy B. Reddy, Eric S. White, Anil G. Jegga, Satish K. Madala
View: Text | PDF
Research Article Pulmonology

Wilms’ tumor 1 drives fibroproliferation and myofibroblast transformation in severe fibrotic lung disease

  • Text
  • PDF
Abstract

Wilms’ tumor 1 (WT1) is a critical transcriptional regulator of mesothelial cells during lung development but is downregulated in postnatal stages and adult lungs. We recently showed that WT1 is upregulated in both mesothelial cells and mesenchymal cells in the pathogenesis of idiopathic pulmonary fibrosis (IPF), a fatal fibrotic lung disease. Although WT1-positive cell accumulation leading to severe fibrotic lung disease has been studied, the role of WT1 in fibroblast activation and pulmonary fibrosis remains elusive. Here, we show that WT1 functions as a positive regulator of fibroblast activation, including fibroproliferation, myofibroblast transformation, and extracellular matrix (ECM) production. Chromatin immunoprecipitation experiments indicate that WT1 binds directly to the promoter DNA sequence of α-smooth muscle actin (αSMA) to induce myofibroblast transformation. In support, the genetic lineage tracing identifies WT1 as a key driver of mesothelial-to-myofibroblast and fibroblast-to-myofibroblast transformation. Importantly, the partial loss of WT1 was sufficient to attenuate myofibroblast accumulation and pulmonary fibrosis in vivo. Further, our coculture studies show that WT1 upregulation leads to non–cell autonomous effects on neighboring cells. Thus, our data uncovered a pathogenic role of WT1 in IPF by promoting fibroblast activation in the peripheral areas of the lung and as a target for therapeutic intervention.

Authors

Vishwaraj Sontake, Rajesh K. Kasam, Debora Sinner, Thomas R. Korfhagen, Geereddy B. Reddy, Eric S. White, Anil G. Jegga, Satish K. Madala

×

Figure 4

WT1 is a positive regulator of fibroproliferation.

Options: View larger image (or click on image) Download as PowerPoint
WT1 is a positive regulator of fibroproliferation.
Primary lung-resident...
Primary lung-resident fibroblasts were isolated from the lung cultures of IPF, non-IPF, WT, or TGFα transgenic mice by negative selection using ant-CD45 magnetic beads. (A) Human non-IPF fibroblasts were transduced with either control adeno or WT1 adenovirus for 72 hours. Proliferation was assessed by immunoblotting WT1 and proliferating cell nuclear antigen (PCNA). PCNA quantification was performed by normalizing to the endogenous β-actin control. Results are representative of 2 independent experiments with similar results (n = 3). (B) Human IPF fibroblasts were transfected with either control or WT1 siRNA for 72 hours, and proliferation was assessed by BrdU incorporation. Results are cumulative of 2 independent experiments with similar results (n = 4). (C) Fibroblasts of nontransgenic mice on Dox for 4 weeks were transduced with either control lenti or WT1 lentivirus for 72 hours. Proliferation was assessed by BrdU incorporation assay. Results are representative of 2 independent experiments with similar results (n = 6). (D) Fibroblasts of TGFα transgenic mice on Dox for 4 weeks were transiently transfected with either control or WT1 siRNA for 72 hours, and proliferation was assessed by BrdU incorporation. Results are cumulative of 2 independent experiments with similar results (n = 4). (E) WT1-driven proliferative genes including Grem1, Runx1, Wnt4, Stat3, Prrx1, Igf1, Ccnb1, and E2f8 were quantified in fibroblasts of TGFα transgenic mice on Dox for 4 weeks transfected with either control or WT1 siRNA for 48 hours. Results are representative of 3 independent experiments with similar results (n = 3). Data are presented as mean ± SEM. Unpaired Student t test *P < 0.05, **P < 0.005, ***P < 0.0005, ****P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts